Business Wire

Seismic Therapeutic Doses First Cohort in Phase 1 Clinical Trial of S‑1117, a Novel Pan‑IgG Protease Therapy for Antibody-Mediated Diseases

WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject cohort in a Phase 1 clinical trial of ...
Seeking Alpha

Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

The Company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime in cardiogenic shock targeting data in a similar timeframe WARRINGTON, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- ...